AzTrials
AzTrials

Labor ComplicationPhase 2GELFREQNCT04413890

Comparison of Two Rhythm of Administration of Prostaglandin Gel for Induction of Labor

A Phase 2 study testing Dinoprostone vaginal gel in people with Labor Complication and Cervix, run by University Hospital Center of Martinique at 1 site in Martinique.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study compares two rhythms of administration of prostaglandin vaginal gels for cervical priming before induction of labor in term patients. In our institution, prostaglandin gels are given for a maximum of three times, with induction by oxytocin and amniotomy the day after the last gel whatever Bishop score has… Read more about this study

Who is it for?
Ages 18 to 49 years, women only
Conditions the study is for
Labor Complication, Cervix
What is being tested?
Dinoprostone vaginal gel
Could I receive a placebo?
No, everyone receives an active treatment
How many people
268 participants
Where
1 siteMartinique
Study dates
17 Dec 2019to 27 Jan 2021
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 49 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patients above 18 years
  • Gestational age ≥ 37 weeks
  • With indicated induction of labor and initial Bishop score under 6
  • Without any contraindication to vaginal delivery
  • Who consent to participate to the clinical research
  • With French Medical Public Insurance

Who cannot join

  • Multiple pregnancy
  • Previous uterine scar (for myomas or cesarean section)
  • Fetus not in cephalic presentation
  • Allergy to prostaglandins
  • Who not consent to participate to the study

Trial locations and contacts

1 site in 1 country.

Martinique1 site
  • University Hospital of Martinique

    Fort-de-France, 97261

Other trials in Martinique

About this study

Official title: Administration of Prostaglandin Gel for Cervical Priming During Induction of Labour Every 12 Hours Versus 24 Hours: a Randomized Superiority Controlled Trial

The study compares two rhythms of administration of prostaglandin vaginal gels for cervical priming before induction of labor in term patients. In our institution, prostaglandin gels are given for a maximum of three times, with induction by oxytocin and amniotomy the day after the last gel whatever Bishop score has been obtained. This management results in some patient spending four days in hospital before delivery. The aim of the study is to compare our classical management scheme with a reduced interval between to gels, of 12h instead of 24 h. The primary outcome will be the time elapsed between the first prostaglandin gel and delivery. Tolerance of both management patterns will also be evaluated through a satisfaction survey.

Read the detailed description

Approximatively 22% of pregnant women have an induction of labor in France (22.9% in our institution in 2019), mainly for prolonged pregnancy after 41 weeks gestational age or prolonged rupture of membranes. Patients whose cervix is considered unripe (Bishop score under 6) are generally proposed a cervical priming because induction of labor without prior priming entails a higher of cesarean delivery rate for failed induction. The devices used for cervical priming are pharmacological (mainly prostaglandin gel, pessaries or suppositories) or mechanical (Foley catheter, Cook balloons). Very few recommendations exist regarding the type of device, the rhythm and maximal number of repeat administrations and the interval between two administrations. Shortening interval between two administrations (in case of use of a device necessitating serial prescriptions) may shorten the time interval between beginning of priming and delivery. In our institution, a vaginal gel can be given three times before induction of labor with oxytocin and amniotomy, whatever Bishop score has been obtained after priming. These gels are given on a daily basis. This rhythm implies than for some women not responding to a first gel, priming can last up to three days, lengthening hospital stay and leading to maternal weariness. Maternal satisfaction during induction of labor is seldom analyzed. An intensification in gel administration implies a change in maternal management during the induction process, with shortened periods of rest between two gels and nearer periods of pain and discomfort, albeit on a theoretically shorter period. The way patients deal with this new rhythm compared to the classical in part of the evaluation in this study. All patients having a singleton pregnancy and an indication for term (≥ 37 weeks gestation age) induction with an unfavorable cervix and no contraindication to vaginal delivery will be eligible. Patients with fetuses in breech presentation, a scarred uterus, under 18 years, bearing a fetus with antenatally known malformation, not fluent in French or presenting an allergy to prostaglandins will be excluded. A written informed consent will be required before inclusion. The primary outcome will be the duration between first priming with prostaglandin gel and delivery. Secondary outcomes will be the satisfaction of patients with their induction process (measured through a survey answered during the in-hospital post-partum stay), the rate of cesarean section, the rate of hypertonia/hypercinesia during priming and induction requiring medical intervention, the length of active phase of labor (after 5 cm of dilation), the oxytocin doses used during delivery for induction or augmentation, initial neonatal (Apgar score, arterial cord pH and lactates, resuscitation maneuvers, transfer to intensive care unit) and maternal (post-partum hemorrhage, hyperthermia during labor, perineal laceration > 2nd degree and endometritis) morbidity and length of total hospital stay. The investigators calculated that a sample of 268 patients (134 in each group) will be necessary to detect a 30% reduction in duration between first priming and delivery in the experimental group (one gel every 12h) compared with the classical group. Mean time frame between first priming and delivery has been measured in our department in 2018 to 31.8 hours (standard deviation 27.6 hours).

Being tested
Dinoprostone vaginal gel
Keywords
Induction, Term, Labor, Rhythm, Prostaglandins
Medical subject headings
Obstetric Labor Complications

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dinoprostone vaginal gelDrug

    Also called cervical priming with prostaglandin gel

    Prostaglandin gel 0.5, 1 or 2 mg

Study groups in NCT04413890
Study groupRoleWhat they receive
Classical administrationActive comparatorOne prostaglandin vaginal gel every 24 hours
Receives: Drug: Dinoprostone vaginal gel
Experimental administrationExperimentalOne prostaglandin vaginal gel every 12 hours
Receives: Drug: Dinoprostone vaginal gel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time between gel administration and delivery

    Time between first gel administration for cervical priming and delivery

    Measured: At inclusion (Day 0)

  2. Time between gel administration and delivery

    Change between cervical priming and delivery

    Measured: At 12 hours or 24 hours (after each gel administration)

  3. Time between gel administration and delivery

    Time between first gel administration for cervical priming and delivery

    Measured: Time 0 after the childbirth

  4. Time between gel administration and delivery

    Time between first gel administration for cervical priming and delivery

    Measured: Until 5 days postpartum (during in-hospital postpartum period)

Secondary outcomes (12)
  1. Maternal satisfaction

    maternal satisfaction measured by survey self-administered during postpartum hospital stay

    Measured: Until 5 days postpartum

  2. Cesarean section rate

    Measured: During labor

  3. Hypertonia / hypercinesia rate

    Hypertonia (rise of uterus tone more than 10 minutes)/hypercinesia (more than 5 uterine contractions per 10 minutes) rate during priming and induction

    Measured: During priming and induction

  4. Oxytocin dose during labor

    Induction or augmentation of Oxytocin doses

    Measured: During labor

  5. Length of active first phase of labor

    Induction or augmentation of active first phase of labor

    Measured: During labor

  6. Maternal morbidity

    Fever during labor, perineal laceration superior to 2nd degree, postpartum hemorrhage, endometritis

    Measured: During labor

  7. Neonatal immediate morbidity

    Assess if Apgar score is less than 7

    Measured: 5 minutes after childbirth

  8. Neonatal immediate morbidity

    Assess of arterial cord pH level

    Measured: 5 minutes after childbirth

  9. Neonatal immediate morbidity

    Assess of arterial cord lactate level

    Measured: 5 minutes after childbirth

  10. Neonatal immediate morbidity

    Concentration of arterial cord lactates level (in Mmol/L)

    Measured: 5 minutes after childbirth

  11. Neonatal immediate morbidity

    Occurence or not of resuscitation maneuvers in delivery room

    Measured: 5 minutes after childbirth

  12. Neonatal immediate morbidity

    Occurence or no transfer of the child to neonatal intensive care unit

    Measured: 5 minutes after childbirth

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jun 2020
  2. Study start17 Dec 2019
  3. Primary completion27 Jan 2021
  4. Study completion27 Jan 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
268 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04413890
Sponsor's protocol ID
19_RIPH2_10
Acronym
GELFREQ
Status last verified
Jul 2023
First submitted
7 Apr 2020
Last updated
19 Jul 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Dinoprostone vaginal gel in people with Labor Complication and Cervix, run by University Hospital Center of Martinique at 1 site in Martinique.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Martinique. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time between gel administration and delivery (time frame: At inclusion (Day 0)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in